 STOCKHOLM, July 15, 2021 PRNewswire -- Calliditas Therapeutics AB Nasdaq: CALT Nasdaq Stockholm: CALTX Calliditas today announced that the company has signed a loan agreement of up to the Euro equivalent of 75 million with Kreos Capital. Proceeds from the loan will be utilized for the launch of Calliditas lead product candidate Nefecon, if approved, as well as to support clinical development efforts and for general corporate purposes. 